technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics. The Company’s customer base has also transitioned from primarily substantial government contracts to now focus almost 100% on commercial activity servicing the biotech marketplace. The Company has retained Paragon’s core scientific talent while expanding its leadership team with new key senior hires who have a proven track record in GMP manufacturing. Each member of the current leadership team has over 20 years of industry experience and serves as the Company’s foundation to build a dominant CDMO in Maryland. Paragon now provides complete manufacturing services from process development and clinical manufacturing through commercial launch at its new 150,000 ft2 facility.